Antiemetic activity of megestrol acetate in patients receiving chemotherapy

@article{Zang2010AntiemeticAO,
  title={Antiemetic activity of megestrol acetate in patients receiving chemotherapy},
  author={Jian Zang and Min Hou and Hongfeng Gou and Meng Qiu and Jing Wang and Xiao Juan Zhou and De-yun Luo and Yu Yang and Ming Jiang and Dan Cao and Feng Bi and Feng Xu and Ya-li Shen and Cheng Yi},
  journal={Supportive Care in Cancer},
  year={2010},
  volume={19},
  pages={667-673}
}
PurposeSeveral trials had independently noted that patients receiving megestrol acetate had less nausea and vomiting, but this antiemetic activity of megestrol acetate has not been reported separately in the literature. Our objective was to evaluate the antiemetic ability of megestrol acetate in patients receiving chemotherapy.Patients and MethodsPatients receiving chemotherapy were randomly assigned to receive either megestrol acetate 320 mg PO or placebo before the first day of chemotherapy… 
Medroxyprogesterone acetate for refractory emesis in cisplatin-treated patients.
TLDR
Medroxyprogesterone acetate is considered to be a potentially promising agent for refractory emesis induced by cisplatin-containing chemotherapy.
Prophylactic treatment for delayed chemotherapy-induced nausea and vomiting after non-AC based moderately emetogenic chemotherapy: a systematic review of randomized controlled trials
TLDR
Superiority of palonosetron over first-generation 5-HT3 receptor antagonists for the prevention of acute and delayed CINV after non-AC MEC has not been proven and NEPA, olanzapine, and megestrol acetate show highly effective complete response (CR) rates.
Recent developments in the prevention of chemotherapy-induced nausea and vomiting (CINV): a comprehensive review.
  • K. Jordan, F. Jahn, M. Aapro
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2015
TLDR
This comprehensive review summarizes the research efforts in this field over the past few years and confirms that dexamethasone-sparing regimens are effective, and demonstrated the value of NK1RAs in high-dose chemotherapy settings as well as with certain moderately emetogenic chemotherapies such as carboplatin.
Efetividade de antieméticos no controle da emese induzida pela quimioterapia antineoplásica, em domicílio
TLDR
Antiemetics were not effective in the prevention or treatment at home, of chemotherapy-induced emesis in women with breast cancer in moderately emetogenic chemotherapy using dexamethasone/ondansetron.
Chapter 162 – Antiemetics and Prokinetics
• The medullary vomiting center (MVC) probably is not a focal, discrete area in the brain; rather, it is spread throughout the medulla. • Centrally acting antiemetics are more effective than

References

SHOWING 1-10 OF 29 REFERENCES
Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia.
TLDR
This study convincingly demonstrated that megestrol acetate can stimulate appetite and food intake in patients with anorexia and cachexia associated with cancer, leading to significant weight gain in a proportion of such patients.
Dronabinol versus megestrol acetate versus combination therapy for cancer-associated anorexia: a North Central Cancer Treatment Group study.
TLDR
In the doses and schedules studied, megestrol acetate provided superior anorexia palliation among advanced cancer patients compared with dronabinol alone, and an improvement in quality of life (QOL) among megestro acetate-treated and combination-treated patients.
Palliative treatment of cancer anorexia with oral suspension of megestrol acetate.
TLDR
Overall quality of life after the daily dose of 480-840 mg of MA was improved in 63, 56, and 55% of patients remaining on therapy after 2, 4, and 8 weeks, respectively, and appetite was the most successfully influenced parameter with an improvement in VAS in 95% of cases after 2 weeks of therapy.
Randomized double-blind placebo-controlled trial of cisplatin and etoposide plus megestrol acetate/placebo in extensive-stage small-cell lung cancer: a North Central Cancer Treatment Group study.
  • K. Rowland, C. Loprinzi, +12 authors J. Jett
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1996
TLDR
Megestrol acetate cannot be routinely recommended for all patients with small-cell lung cancer at the time of chemotherapy initiation, but its therapeutic ratio may be more favorable for patients with problematic cancer anorexia/cachexia.
New antiemetic drugs.
  • F. Roila, S. Fatigoni
  • Medicine
    Annals of oncology : official journal of the European Society for Medical Oncology
  • 2006
TLDR
A critical review of the results of published studies of aprepitant, a new NK1 receptor antagonist, and of palonosetron, a 5-HT3 receptor antagonist with a longer half-life found both showed superior or similar efficacy to ondansetron and dolasetron in patients submitted to moderately emetogenic chemotherapy.
Advanced breast cancer: response to high dose oral medroxyprogesterone acetate.
TLDR
Seven out of 24 patients who had not received prior endocrine therapy responded to high dose oral MPA, a response rate similar to that seen following other hormonal manipulations, but because the drug also has activity against hormone-resistant tumours and is well tolerated, it should have role in the treatment of advanced breast cancer.
Chemotherapy-induced nausea and vomiting: the importance of acute antiemetic control.
TLDR
Evidence suggests that the 5-HT(3)-receptor antagonists administered in combination with corticosteroids afford the best protection from symptoms of acute emesis and, by extrapolation, the most effective prevention of delayed emesis.
Proposal for classifying the acute emetogenicity of cancer chemotherapy.
  • P. Hesketh, M. Kris, +6 authors C. Lindley
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 1997
TLDR
The proposed classification schema provides a practical means to determine the emetogenic potential of individual chemotherapy agents and combination regimens during the 24 hours after administration and can serve as a framework for the development of antiemetic guidelines.
Phase III randomized placebo-controlled trial of two doses of megestrol acetate as treatment for menopausal symptoms in women with breast cancer: Southwest Oncology Group Study 9626.
  • J. W. Goodwin, S. Green, +6 authors K. Albain
  • Medicine
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology
  • 2008
TLDR
MA significantly reduced vasomotor symptoms with durable benefit over 6 months and MA 20 mg/d is the preferred dose.
A brief intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for advanced non-small cell lung cancer: results of a phase II trial.
TLDR
A brief, intensive cisplatin-based outpatient chemotherapy regimen with filgrastim and megestrol acetate support for patients with stage IIIB and IV non-small cell lung cancer and a favorable performance status appears to be similar in efficacy to the most active regimens reported by other investigators.
...
1
2
3
...